Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference

From Startup Aptinyx

Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-present-37th-annual-jp-morgan-healthcare-conference

EVANSTON, Ill., Jan. 02, 2019 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 8th, 2019 at 4:00 p.m. PST at the Westin St. Francis Hotel in San Francisco.
A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for up to 30 days following the event.
About AptinyxAptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for the discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Investor Contacts:Nick SmithAptinyx Inc.ir@aptinyx.com847-871-0377
Rachel FrankStern Investor Relationsrachelf@sternir.com212-362-1200
Media Contact:Jordann PhillipsCanale Communicationsjordann@canalecomm.com619-849-6009
Source: Aptinyx Inc.

Source: Aptinyx Inc.

Please visit their site for more information: Aptinyx.com

All,Biotechnology,Healthcare News,Startup News
2019-01-02 20:03:59